Syntara Ltd
ASX:SNT

Watchlist Manager
Syntara Ltd Logo
Syntara Ltd
ASX:SNT
Watchlist
Price: 0.067 AUD 8.06% Market Closed
Market Cap: 92m AUD
Have any thoughts about
Syntara Ltd?
Write Note

Syntara Ltd
Total Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Syntara Ltd
Total Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Syntara Ltd
ASX:SNT
Total Liabilities
AU$5.7m
CAGR 3-Years
-43%
CAGR 5-Years
-32%
CAGR 10-Years
-19%
Mayne Pharma Group Ltd
ASX:MYX
Total Liabilities
AU$689m
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Total Liabilities
AU$9m
CAGR 3-Years
56%
CAGR 5-Years
47%
CAGR 10-Years
15%
Botanix Pharmaceuticals Ltd
ASX:BOT
Total Liabilities
AU$3.7m
CAGR 3-Years
48%
CAGR 5-Years
-4%
CAGR 10-Years
28%
Probiotec Ltd
ASX:PBP
Total Liabilities
AU$143.1m
CAGR 3-Years
11%
CAGR 5-Years
19%
CAGR 10-Years
14%
Arovella Therapeutics Ltd
ASX:ALA
Total Liabilities
AU$2.1m
CAGR 3-Years
6%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
No Stocks Found

Syntara Ltd
Glance View

Market Cap
92m AUD
Industry
Pharmaceuticals

Syntara Ltd is a AU-based company operating in Pharmaceuticals industry. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. Syntara Limited, formerly Pharmaxis Ltd, is an Australia-based clinical-stage drug development company with a focus on blood-related cancers. The Company’s highly productive drug discovery engine is driven by its expertise in amine oxidase inhibitors. Its lead candidate, PXS-5505, is used for the bone marrow cancer myelofibrosis, which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its PXS-4728 is a SSAO/MAOB inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis, and cardiac fibrosis. The company has developed two respiratory products: Bronchitol, for cystic fibrosis, and Aridol, a lung function test.

SNT Intrinsic Value
0.052 AUD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Syntara Ltd's Total Liabilities?
Total Liabilities
5.7m AUD

Based on the financial report for Jun 30, 2024, Syntara Ltd's Total Liabilities amounts to 5.7m AUD.

What is Syntara Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
-19%

Over the last year, the Total Liabilities growth was -61%. The average annual Total Liabilities growth rates for Syntara Ltd have been -43% over the past three years , -32% over the past five years , and -19% over the past ten years .

Back to Top